Compare Quest Diagnostics Inc (DGX) vs VF Corp (VFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs VF Corp — how do they compare? Quest Diagnostics Inc trades at $231.53 (market cap $25.48B), while VF Corp trades at $14.74 (market cap $5.71B). The key difference: Quest Diagnostics Inc is far larger — about 4.5× VF Corp's market cap, and VF Corp pays the higher dividend (2.48%). Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and VF Corp for 64 Days on average.
| DGX | VFC | |
|---|---|---|
Market Cap | $25.48B | $5.71B |
Volume | 941,866 | 8,987,330 |
Sector | Health | Consumer Cyclical |
52-Week High | $247.45 | $21.55 |
52-Week Low | $173.49 | $12.62 |
Typical Hold Time | 56 Days | 64 Days |
Enterprise Value | $31.23B | $10.00B |
Dividend Yield | 1.49% | 2.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $227.00, down 0.64% with a bearish technical signal. The company shows strong fundamentals with three consecutive quarterly earnings beats and revenue growth from $9.9B in 2024 to $11.0B in 2025. Recent developments include positive clinical study results and a new Apple Health integration, though Medicare reimbursement cuts pose headwinds. The stock trades near support at $226 with oversold RSI readings suggesting potential for near-term bounce.
DGX presents a mixed outlook with solid execution offset by regulatory risks. The 10% upside to consensus price target of $250 offers opportunity, but Medicare payment reductions and rising debt levels require monitoring. Recent earnings momentum and strategic partnerships support growth, making DGX suitable for investors comfortable with healthcare sector volatility.
VFC trades at $14.38, down 0.48% with a bullish technical signal from moving averages. The company shows mixed fundamentals with revenue declining from $11.8B in 2022 to $9.5B in 2025, while profitability remains challenged with negative net income of -$189.72M. Recent earnings show volatility with one beat and two misses in the last four quarters. The stock trades at attractive valuation multiples with P/E of 21.06 and P/S of 0.61, below industry averages.
VFC presents a turnaround opportunity with discounted valuation and improving cash flow projections for 2026, but faces significant execution risks from Vans brand weakness and ongoing debt reduction challenges. Analyst consensus leans neutral with 52% hold rating and $18.33 price target suggesting 27% upside potential, though recent dividend cuts and brand-specific headwinds require careful monitoring of Q3 earnings performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About VF Corp
VF designs, produces, and distributes branded apparel and accessories. Its largest apparel categories include action sports, outdoor, and workwear. Its portfolio of about a dozen brands includes Vans, The North Face, Timberland, Supreme, and Dickies. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. The company has grown through multiple acquisitions and traces its roots to 1899.
Read more on VFC →
